MedTrace Logo

Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC

NCT04043195 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-05-28

No results posted yet for this study

Summary

The purpose of this study is to examine the safety and efficacy of combining Nivolumab and low-dose Oxaliplatin with or without Ipilumumab in patients who have had their advanced NSCLC cancer worsen on or after being treated with certain immunotherapies (drugs that target the immune system).

Conditions

  • Advanced NSCLC

Interventions

DRUG

Nivolumab

240 mg every 2 weeks. Nivolumab will continue for up to 2 years.

DRUG

Oxaliplatin

65 mg/m2 every 2 weeks. Oxaliplatin will continue for up to 12 cycles.

DRUG

Ipilimumab

1 mg/kg every 6 weeks. Ipilimumab will continue for up to 4 cycles

Sponsors & Collaborators

  • Hatim Husain

    lead OTHER

Principal Investigators

  • Hatim Husain · University of California, San Diego

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-14
Primary Completion
2025-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04043195 on ClinicalTrials.gov